Download Files:
Fluphenazine (dimaleate)
SKU
HY-119980A-Get quote
Category Reference compound
Tags Anti-infection;GPCR/G Protein;Membrane Transporter/Ion Channel;Neuronal Signaling, Dopamine Receptor;SARS-CoV;Sodium Channel, Infection; Neurological Disease
Products Details
Product Description
– Fluphenazine dimaleate is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dimaleate blocks neuronal voltage-gated sodium channels. Fluphenazine dimaleate acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dimaleate can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dimaleate can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2[1][2][3][4][6].
Web ID
– HY-119980A
Shipping
– Room temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C30H34F3N3O9S
References
– [1]Siragusa S, Bistas KG, Saadabadi A. Fluphenazine. 2022 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan.|[2]Davis JL, et al. Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine. JAMA. 1977 Nov 21;238(21):2291-2.|[3]Abdel-Hamid HA, et al. Teratogenic effect of diphenylhydantoin and/or fluphenazine in mice. J Appl Toxicol. 1996 May-Jun;16(3):221-5.|[4]LangwiÅ„ski R, Niedzielski J. Narcotic analgesics and stereotyped behaviour in mice. Naunyn Schmiedebergs Arch Pharmacol. 1980 Jul;312(3):225-7.|[5]Zhou X, et al. The neuroleptic drug, fluphenazine, blocks neuronal voltage-gated sodium channels. Brain Res. 2006 Aug 23;1106(1):72-81.|[6]Nazeam J, et al. Based on Principles and Insights of COVID-19 Epidemiology, Genome Sequencing, and Pathogenesis: Retrospective Analysis of Sinigrin and ProlixinRX (Fluphenazine) Provides Off-Label Drug Candidates. SLAS Discov. 2020 Dec;25(10):1123-1140.
CAS Number
– 3093-66-1
Molecular Weight
– 669.67
SMILES
– OCCN(CC1)CCN1CCCN2C3=CC(C(F)(F)F)=CC=C3SC4=CC=CC=C42.OC(/C=CC(O)=O)=O.OC(/C=CC(O)=O)=O
Clinical Information
– Launched
Research Area
– Infection; Neurological Disease
Solubility
– 10 mM in DMSO
Target
– Dopamine Receptor;SARS-CoV;Sodium Channel
Pathway
– Anti-infection;GPCR/G Protein;Membrane Transporter/Ion Channel;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.